Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing

Conclusion:This study demonstrates that biweekly bevacizumab injections are effective in nearly one-quarter of nAMD non-responders with no adverse events reported. Switching earlier, rather than later, to this low cost modality may be of benefit for a portion of non-responders to conventional treatment.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research